Type 2 Diabetes


Clinical Trial Title

Type 2 Diabetes

Trial Status

Open to Enrollment

Start Date

January 1, 2013

Trial Type


Specific Condition

Type 2 diabetes


To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.

Eligibility Criteria

Inclusion Criteria:

  • At least 18 years old
  • Diagnosed with type 2 diabetes mellitus
  • HbA1c of 7.1% to 11.0%, inclusive, at screening
  • Has stable body weight, i.e., not varying by >3% for at least 3 months prior to screening
  • Fasting plasma glucose concentration <280 mg/dL (15.5 mmol/L) at screening
  • Body mass index of <45 kg/m2 at screening
  • Has been treated with a stable regimen of ≥1500 mg/day metformin for a minimum of 2 months prior to Visit 1 (Screening)


Exclusion Criteria - contact study coordinator.

IRB Number


Principal Investigator Name

James Neifing, MD

Contact Name

Tammy Mayfield



Contact E-Mail


Last Updated: Wednesday, September 18, 2013 01:53:59 PM